This program is intended for hematologists and other healthcare professionals who care for patients with cold agglutinin disease.
The goal of this program is to improve the knowledge and competence of learners at integrating new agents into treatment of patients with cold agglutinin disease
Evaluate the role of complement pathways in the pathophysiology of cold agglutinin disease and associated clinical manifestations in patients with hemolytic anemia
Apply current diagnostic criteria for cold agglutinin disease in patients displaying signs and symptoms of autoimmune hemolytic anemia to facilitate an accurate and timely diagnosis
Assess the clinical rationale for therapies that inhibit complement-mediated hemolysis in cold agglutinin disease
Plan targeted treatment strategies for patients with cold agglutinin disease based on expert recommendations on up-to-date safety and efficacy data and currently approved indications
Implement an individualized treatment and supportive care plan for patients with cancer who develop cold agglutinin disease based on patient-specific characteristics
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Catherine M. Broome, MD
Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Catherine M. Broome, MD: consultant/advisor/speaker: Alexion, Argenx, Incyte, Sanofi; researcher: Alpine, Rigel, Star Therapeutics.
David Dingli, MD, PhD
Professor of Medicine
Division of Hematology
Mayo Clinic College of Science and Medicine
David Dingli, MD, PhD: consultant/advisor/speaker: Alexion, Apellis Pharmaceuticals, AstraZeneca, Janssen, Novartis, Sanofi; data safety monitoring board: Sorrento Therapeutics.
Deva Sharma, MD, MS
Assistant Professor of Medicine
Divisions of Transfusion Medicine & Hematology-Oncology
Vanderbilt University Medical Center
Deva Sharma, MD, MS: consultant/advisor/speaker: Novo Nordisk, Sanofi, Terumo Blood and Cell Technologies.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 20, 2023, through December 19, 2024:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.